Checkpoint Therapeutics (OTCQX: CKPT) is an immuno-oncology biopharmaceutical company focused on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company develops a portfolio of human immuno-oncology targeted antibodies. Its products pipeline includes Anti-PD-L1, a preclinical human antagonistic antibody designed to bind to PD-L1 and block its interaction with programmed cell death protein 1; and Anti-GITR, a human agonistic antibody that binds and triggers signaling in glucocorticoid-induced TNFR related protein expressing cells. The company is also developing CK-101, an oral covalent inhibitor, which is in preclinical stage for the treatment of lung cancer; CK-102 that is in phase Ib clinical trial for the treatment of multiple forms of cancer; and Anti-CAIX, which is preclinical trial for the treatment of renal cell carcinoma. It has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. For more information, visit the company’s website at www.checkpointtx.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
